RT Journal Article
T1 Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice
A1 Aguilera, Yolanda
A1 Mellado-Damas, Nuria
A1 Olmedo-Moreno, Laura
A1 López, Víctor
A1 Panadero-Morón, Concepción
A1 Benito, Marina
A1 Guerrero-Cázares, Hugo
A1 Márquez-Vega, Catalina
A1 Martín-Montalvo, Alejandro
A1 Capilla-González, Vivian
K1 Mesenchymal stem cells
K1 Cell therapy
K1 Intranasal delivery
K1 Biosafety
K1 Nervous system disorders
K1 Células madre mesenquimatosas
K1 Tratamiento basado en trasplante de células y tejidos
K1 Contención de riesgos biológicos
K1 Enfermedades del sistema nervioso
AB Mesenchymal stem cell (MSC)-based therapy is a promising therapeutic approach in the management of several pathologies, including central nervous system diseases. Previously, we demonstrated the therapeutic potential of human adipose-derived MSCs for neurological sequelae of oncological radiotherapy using the intranasal route as a non-invasive delivery method. However, a comprehensive investigation of the safety of intranasal MSC treatment should be performed before clinical applications. Here, we cultured human MSCs in compliance with quality control standards and administrated repeated doses of cells into the nostrils of juvenile immunodeficient mice, mimicking the design of a subsequent clinical trial. Short- and long-term effects of cell administration were evaluated by in vivo and ex vivo studies. No serious adverse events were reported on mouse welfare, behavioral performances, and blood plasma analysis. Magnetic resonance study and histological analysis did not reveal tumor formation or other abnormalities in the examined organs of mice receiving MSCs. Biodistribution study reveals a progressive disappearance of transplanted cells that was further supported by an absent expression of human GAPDH gene in the major organs of transplanted mice. Our data indicate that the intranasal application of MSCs is a safe, simple and non-invasive strategy and encourage its use in future clinical trials.
PB MDPI
YR 2021
FD 2021-03-09
LK http://hdl.handle.net/10668/4260
UL http://hdl.handle.net/10668/4260
LA en
NO Aguilera Y, Mellado-Damas N, Olmedo-Moreno L, López V, Panadero-Morón C, Benito M, et al. Preclinical Safety Evaluation of Intranasally Delivered Human Mesenchymal Stem Cells in Juvenile Mice. Cancers. 2021 Mar 9;13(5):1169.
DS RISalud
RD Apr 18, 2025